AptarGroup, Inc. Q3 2025 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. AptarGroup, Inc. is a global manufacturer of dispensing, dosing, and protection technologies for the pharmaceutical, beauty, and food/beverage markets. The company operates through three segments: Aptar Pharma, Aptar Beauty, and Aptar Closures.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Net Sales | $961.1 million | $909.3 million | $2.81 billion | $2.73 billion |
| Operating Income | $136.9 million | $138.3 million | $394.8 million | $376.4 million |
| Net Income (Attributable to Aptar) | $127.9 million | $100.0 million | $318.4 million | $273.6 million |
| Diluted EPS | $1.92 | $1.48 | $4.75 | $4.05 |
| Adjusted EBITDA | $222.6 million | $208.4 million | $624.3 million | $580.0 million |
| Free Cash Flow (9M) | $206.0 million (vs. $254.8 million prior year) | |||
| Cash & Equivalents | $257.1 million (as of Sept 30, 2025) | |||
| Total Debt | $1.20 billion (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2025 net sales increased 6% year-over-year. Core sales (excluding currency and acquisitions) grew 1%, driven by volume growth in Pharma and Closures segments, offsetting lower tooling sales and resin cost pass-throughs.
- Profitability: Operating income decreased slightly in Q3 ($1.4 million decline) due to higher costs of sales, depreciation, and legal expenses, despite revenue growth. However, YTD operating income increased 5%.
- One-Time Gains: Net income was significantly boosted by a $26.5 million pre-tax gain from the remeasurement of an equity method investment (BTY) upon consolidation following a call option exercise in July 2025.
- Acquisitions: The company acquired an additional 31% interest in BTY (China-based beauty packaging), increasing ownership to 80%. An agreement was also signed to acquire Sommaplast (Brazil-based pharma packaging) for $30–$35 million, expected to close in Q4 2025.
- Cost Structure: Cost of sales as a percentage of net sales increased to 62.2% in Q3 (from 61.4% in Q3 2024) due to lower margin product mix and input costs. SG&A expenses rose primarily due to higher legal fees.
Guidance, Outlook, and Risks
- Q4 2025 Guidance: Management expects Adjusted EPS in the range of $1.20 to $1.28, based on an effective tax rate of 19.5% to 21.5%.
- Capital Expenditures: Total 2025 estimated cash outlays for CapEx are expected to be approximately $250 million to $270 million.
- Legal Proceedings:
- ARS Pharmaceuticals: Aptar filed suit alleging trade secret misappropriation; ARS countersued alleging antitrust violations.
- Nemera: Patent infringement actions in Germany and France regarding ophthalmic products. An EPO hearing in October 2025 invalidated Nemera's main patent claim, though amended claims continue.
- Contingencies: The company faces customs duty assessments totaling approximately $10–$11 million in principal plus interest/penalties, with no liability currently recorded due to uncertainty in settlement probability.
- Share Repurchases: $190 million of common stock was repurchased in the first nine months of 2025. Approximately $272.7 million remains available under the current $500 million authorization.
Investor Verification Checklist
- BTY Acquisition Impact: Verify the integration progress of the BTY acquisition and the sustainability of the $26.5 million remeasurement gain, which is non-recurring.
- Legal Exposure: Monitor the status of the antitrust counter-suit by ARS Pharmaceuticals and the ongoing Nemera patent litigation, as unfavorable outcomes could impact margins or operations.
- Margin Pressure: Assess the trajectory of Cost of Sales (COS) as a percentage of revenue, which rose in Q3 due to input costs and product mix shifts.
- Debt Levels: Review the increase in total debt to $1.20 billion and the utilization of the revolving credit facility ($339.6 million drawn) against the company's leverage covenants (currently 1.22x).
- Core Sales Momentum: Confirm if the 1% core sales growth is sustainable given the headwinds in tooling sales and the competitive landscape in the beauty segment.